An Open-label, Phase 2 Study of ACP-196 (acalabrutinib) in Subjects With Mantle Cell Lymphoma

Study identifier:ACE-LY-004

ClinicalTrials.gov identifier:NCT02213926

EudraCT identifier:2014-002117-28

CTIS identifier:N/A

Recruitment Complete

Official Title

An Open-label, Phase 2 Study of ACP-196 in Subjects With Mantle Cell Lymphoma

Medical condition

Mantle Cell Lymphoma (MCL)

Phase

Phase 2

Healthy volunteers

No

Study drug

ACP-196 (acalabrutinib)

Sex

All

Actual Enrollment

124

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 02 Mar 2015
Primary Completion Date: 04 Dec 2020
Estimated Study Completion Date: 01 Sept 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2024 by AcertaPharma

Sponsors

AcertaPharma

Collaborators

-

Inclusion and exclusion criteria